Safety and Efficacy of a Sublingual Specific Immunotherapy With an Extract of a Six Grass Pollen Mixture - Full Text View

Safety and Efficacy of a Sublingual Specific Immunotherapy With an Extract of a Six Grass Pollen Mixture

This study is ongoing, but not recruiting participants.

Sponsored by:	Allergopharma Joachim Ganzer KG
Information provided by:	Allergopharma Joachim Ganzer KG
ClinicalTrials.gov Identifier:	NCT00264459

Purpose

The trial is performed to asses efficacy and safety of a sublingual extract of a six grass pollen mixture

Condition	Intervention	Phase
Grass Pollen Allergy	Biological: Grass pollen formulation	Phase III

MedlinePlus related topics:

Allergy Hay Fever

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Official Title:	A Multicentre, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of a Perennial Sublingual Specific Immunotherapy With a Liquid Formulation of an Extract of a Six Grass Pollen-Mixture in Patients With Clinically Relevant Grass Pollen Sensitivity.

Further study details as provided by Allergopharma Joachim Ganzer KG:

Study Start Date:	February 2003
Estimated Study Completion Date:	December 2009

Eligibility

Ages Eligible for Study:	18 Years to 60 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Rhinitis, Rhinoconjunctivitis, Positive Rast result to grass pollen, Positive skin prick test to grass pollen, Positive specific provocation to grass pollen,

Exclusion Criteria:

Serious chronic diseases, Other perennial allergies

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00264459

Locations


Germany
	Allergopharma Joachim Ganzer KG
	Reinbek, Germany, 21465

Sponsors and Collaborators

Allergopharma Joachim Ganzer KG

Investigators


Principal Investigator:	Ludger Klimek, M.D.	unaffiliated

More Information

Leader in specific allergy research and therapy This link exits the ClinicalTrials.gov site

Study ID Numbers:	Al0102st
First Received:	December 12, 2005
Last Updated:	July 24, 2008
ClinicalTrials.gov Identifier:	NCT00264459
Health Authority:	Germany: Paul-Ehrlich-Institut

Keywords provided by Allergopharma Joachim Ganzer KG:

Sublingual immunotherapy

Rhinoconjunctivitis

Rhinitis

Asthma

Study placed in the following topic categories:

Hypersensitivity

Otorhinolaryngologic Diseases

Respiratory Tract Diseases

Rhinitis, Allergic, Seasonal

Hypersensitivity, Immediate

Asthma

Rhinitis

Respiratory Hypersensitivity

Additional relevant MeSH terms:

Immune System Diseases

Nose Diseases

ClinicalTrials.gov processed this record on October 10, 2008